Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02406235 · ClinicalTrials.gov registry record
Evaluating a Novel Onco-genetic BRCA Testing Counselling Model Among Patients With Ovarian Cancer
A clinical trial, sponsored by AstraZeneca.
- Completed
- Registry status
- 710
- Enrollment target
NCT02406235: Completed study, sponsored by AstraZeneca.
NCT02406235 is a clinical trial that has completed, run by AstraZeneca. The registered enrollment target is 710 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02406235 has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- 710 participants
- Enrollment target
Study Summary
The overall objective of this study is to assess turnaround time, pre-BRCA test onco-genetic counselling quality and satisfaction with a new onco-genetic BRCA testing model.
Primary Outcome
The primary objectives include a) assessing turnaround time with the new BRCA (Breast Cancer)-testing pathway; b) patient's assessment of pre-BRCA test onco-genetic counselling quality and satisfaction with the onco-genetic BRCA testing pathway; c) oncologists, and genetic counsellor's assessment of onco-genetic BRCA testing process. The study will be limited to patients with a diagnosis of ovarian cancer.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 710 participants |
| Start Date | 2015-04-21 |
| Est. Completion | 2016-09-30 |
What the finished NCT02406235 record still lists
NCT02406235 is an observational study that tracks outcomes without assigning an intervention. The registered 710 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT02406235 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02406235 about?
NCT02406235 is a clinical study titled "Evaluating a Novel Onco-genetic BRCA Testing Counselling Model Among Patients With Ovarian Cancer". The overall objective of this study is to assess turnaround time, pre-BRCA test onco-genetic counselling quality and satisfaction with a new onco-genetic BRCA testing model.
What is the current status of trial NCT02406235?
This trial is currently completed. The enrollment target is 710 participants. The study started on 2015-04-21. Estimated completion is 2016-09-30.
Who is sponsoring clinical trial NCT02406235?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06179160 · 710 participants · Phase 1
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
- NCT06235697 · 710 participants · Phase 3
Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment
- NCT06470867 · 710 participants · NA
Randomized Controlled Effectiveness Trial of VA S.A.V.E.
- NCT07022483 · 710 participants · Phase 3
Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI